Trial NCT04350320 ; EUDRACT 2020-001511-2
Publication Pascual-Figal DA, Int J Gen Med, 2021
Primary outcome on the report: 1) Change in the WHO 7-points ordinal clinical scale during the 28 days of treatment; 2) effect on IL-6 levels, as main surrogated marker of inflammatory response

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.